GlassScriptPhysician profile
Marlee Ponder
NPI 1265031637
$6,445.82
in general payments reported to CMS, 2019-2025
38 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,742 · 2022: $2,890 · 2023: $40.75 · 2024: $184 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,679.11 | 2021-2025 | Wegovy |
| Abbvie INC. | $913.34 | 2021-2025 | |
| Lilly USA, LLC | $506.80 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $405.08 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $355.24 | 2021-2022 | |
| Esperion Therapeutics, INC. | $236.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.32 | 2021-2022 | |
| Amgen INC. | $165.14 | 2021-2022 | |
| Amarin Pharma, INC. | $158.35 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $145.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.13 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $130.35 | 2021-2025 | |
| Gilead Sciences, INC. | $118.58 | 2022-2025 | |
| Dexcom, INC. | $118.07 | 2021-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlee Ponder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.